Yahoo
NasdaqGS - Delayed Quote USD

COMPASS Pathways plc (CMPS)

8.44 -0.45 (-5.06%)
At close: April 28 at 4:00:01 PM EDT
8.52 +0.08 (+0.95%)
Pre-Market: 9:07:07 AM EDT
Trade CMPS on Coinbase
Chart Range Bar
Loading chart for CMPS
  • Previous Close 8.89
  • Open 8.75
  • Bid 6.44 x 200
  • Ask 10.81 x 200
  • Day's Range 8.39 - 8.97
  • 52 Week Range 2.25 - 10.21
  • Volume 3,107,064
  • Avg. Volume 4,187,185
  • Market Cap (intraday) 1.139B
  • Beta (5Y Monthly) 2.02
  • PE Ratio (TTM) --
  • EPS (TTM) -3.08
  • Earnings Date (est.) May 7, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 21.69

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

compasspathways.com

156

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview: CMPS

Trailing total returns as of 4/29/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

CMPS
25.60%
MSCI WORLD (^990100-USD-STRD)
4.09%

1-Year Return

CMPS
117.53%
MSCI WORLD (^990100-USD-STRD)
26.45%

3-Year Return

CMPS
5.24%
MSCI WORLD (^990100-USD-STRD)
62.62%

5-Year Return

CMPS
76.50%
MSCI WORLD (^990100-USD-STRD)
55.63%

Earnings Trends: CMPS

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -56.79M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-40M
-20M
0

Analyst Insights: CMPS

View More

Analyst Price Targets

8.00
21.69 Average
8.44 Current
70.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/28/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 70 -> 70

Statistics: CMPS

View More

Valuation Measures

Annual
As of 4/28/2026
  • Market Cap

    1.14B

  • Enterprise Value

    1.02B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    16.11

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.68%

  • Return on Equity (ttm)

    -565.28%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -287.86M

  • Diluted EPS (ttm)

    -3.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    149.61M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    97.14M

Compare To: CMPS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: CMPS

Fair Value

8.44 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: